MediciNova Highlights Strategic Focus On Non-Dilutive Funding With NIH-Funded ALS Trial And Canadian Long COVID Study, Reports Strong $42.3M Cash Position, And Reaffirms Commitment To Sustainable Growth And Shareholder Transparency

美第奇新星生物技術強調了其在非稀釋融資方面的戰略重點，包括由NIH資助的ALS試驗和加拿大的長期新冠研究，報告強勁的4230萬美元現金狀況，並重申對可持續增長和股東透明度的承諾

Benzinga · 2024/11/19 22:17

To our esteemed stockholders,

致我們尊敬的股東，

Since its founding, MediciNova has been clear in its mission to deliver new treatment options to the patients suffering with unmet medical needs. In service of that mission, we have been steadfast in our commitment to both further our science in partnership with some of the greatest minds across the United States, and to do so in a way that preserves capital and provides optimal value to shareholders.

美第奇新星生物技術自創立以來，始終秉承其使命，致力於爲患有未滿足醫療需求的患者提供新的治療選擇。爲實現這一使命，我們始終堅定地與美國一些頂尖智慧合作，推動科學，以一種既保全資本又爲股東提供最佳價值的方式。

Our recently announced collaboration to supply our compound MN166 (ibudilast) as part of an NIH-funded expanded access clinical trial is illustrative of this commitment, as it provides the...

我們最近宣佈的合作項目，爲了供應我們的化合物MN166（...

登入免費觀看全文

登入/註冊

譯文內容由第三人軟體翻譯。

以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。

MediciNova Highlights Strategic Focus On Non-Dilutive Funding With NIH-Funded ALS Trial And Canadian Long COVID Study, Reports Strong $42.3M Cash Position, And Reaffirms Commitment To Sustainable Growth And Shareholder Transparency

MediciNova Highlights Strategic Focus On Non-Dilutive Funding With NIH-Funded ALS Trial And Canadian Long COVID Study, Reports Strong $42.3M Cash Position, And Reaffirms Commitment To Sustainable Growth And Shareholder Transparency

風險及免責聲明

聲明